BIOADAPTIVES, INC.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
BDPTStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOW
| Year ended | ||||
|---|---|---|---|---|
| December 31, | ||||
| 2024 · 2023 | ||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||
| Net loss | $(899,161) | $(712,466) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Change in fair value of derivative liabilities | 210,043 | 307,412 | ||
| Impairment of patent | 18,000 | - | ||
| Impairment of inventory | 81,350 | - | ||
| Amortization of license and patent | 1,941 | 28,174 | ||
| Amortization of debt discount | 52,592 | 119,555 | ||
| Management Compensation | 208,871 | - | ||
| Loss on settlement of debt | - | 13,200 | ||
| Unrealized (gain) loss on investments in marketable securities | - | 42 | ||
| Changes in operating assets and liabilities: | ||||
| Inventory | (25,184) | (6,404) | ||
| Security deposit | - | (2,500) | ||
| Prepaid expense and other current assets | 57,200 | (10,000) | ||
| Accounts payable and accrued liabilities | 44,831 | 39,684 | ||
| Due to related party | - | (470) | ||
| Net Cash Used in Operating Activities | (249,517) | (223,773) | ||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||
| Proceeds from issuance for common stock | - | 178,100 | ||
| Proceed from related party | - | 51,044 | ||
| Repayment to related party | - | (50,000) | ||
| Proceeds from notes payable | 32,096 | - | ||
| Proceeds from convertible notes | - | 80,000 | ||
| Proceeds from issuance for preferred stock | 294,115 | - | ||
| Net Cash Provided by Financing Activities | 326,211 | 259,144 | ||
| Net change in cash | 76,694 | 35,371 | ||
| Cash at beginning of period | 60,776 | 25,405 | ||
| Cash at end of period | $137,470 | $60,776 | ||
| SUPPLEMENTAL CASH FLOW INFORMATION: | ||||
| Cash paid for income taxes | $ | - | $ | - |
| Cash paid for interest | $ | - | $ | - |
| NON-CASH INVESTING AND FINANCING ACTIVITIES | ||||
| Derivative liability recognized as debt discount | $ | - | $150,000 | |
| Issuance of common stock for conversion of debt | $202,643 | $282,111 | ||
| Issuance of Series A preferred stock for license fee | $1,500 | $22,625 | ||
| Issuance of Series B preferred stock for license fee | $3,000 | $18,000 | ||
| Issuance of Series B preferred stock for settlement of debt - related party | $1,500 | $16,500 | ||
| Issuance of Series C preferred stock for purchase of inventory | $60,000 | $ | - | |
| Stock payable for consulting service | $150,000 | $ | - | |
| Debt Forgiveness | $310,245 | $ | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.